Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2020, specifically reporting on a transaction involving Persons Discharging Managerial Responsibilities (PDMR). The filing details the vesting of awards under the 2017 Performance Share Plan (PSP) for the Chief Executive Officer, Ms. Emma Walmsley, which occurred on July 27, 2020.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. Instead, it provides specific performance data used to calculate executive compensation vesting for the three-year period ending December 31, 2019:
- Adjusted Free Cash Flow: Achieved £13 billion (Target for maximum vesting: £12.95 billion).
- R&D New Product Sales: Achieved £7.254 billion (Target for maximum vesting: £5.099 billion; Threshold: £4.172 billion).
- Total Shareholder Return (TSR): Ranked 8th out of 10 comparator companies (Below threshold for vesting).
- Share Price: The closing price of Ordinary Shares on July 27, 2020, was £15.834.
Material Changes and Transaction Details
The primary material event is the vesting of 33.334% of the CEO's 2017 PSP award, while 66.666% of the award lapsed due to the TSR performance metric not meeting the threshold. The vesting details are as follows:
- Transaction Date: July 27, 2020.
- Instrument: 277,623 Ordinary Shares (including accrued dividends).
- Transaction Price: £0.00 (Vesting event).
- Future Vesting: The vested shares are now subject to an additional two-year vesting period applicable to Executive Directors.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks. The document is strictly a regulatory notification regarding executive compensation. The only contingency noted is the conditional nature of the award vesting based on the three performance measures (Adjusted Free Cash Flow, TSR, and R&D New Products), where the TSR metric failed to trigger vesting for one-third of the award.
Key Facts for Investor Verification
- Verify the calculation of Adjusted Free Cash Flow (£13bn) and R&D New Product Sales (£7.254bn) against the company's 2018 Annual Report and subsequent financial statements to confirm the basis for the 100% vesting on these metrics.
- Confirm the composition of the comparator group used for the Total Shareholder Return ranking, as the 8th place ranking resulted in zero vesting for that portion of the award.
- Note that the 277,623 shares vested on July 27, 2020, are not immediately liquid; they are subject to a mandatory two-year holding period.
- Confirm that this filing does not represent a change in the company's overall financial position or strategic direction, but rather a routine disclosure of executive equity compensation.